Skip to content

US · AFJKU · SHELL COMPANIES

Aimei Health Technology Co., Ltd Unit (AFJKU) intrinsic value and stock valuation

$23.83as of 2026-09-18 · Mkt cap 73.15M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aimei Health Technology Co., Ltd Unit DCF and intrinsic value

InvestorsCraft values AFJKU with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AFJKU’s statements →

Aimei Health Technology Co., Ltd Unit Graham Number

Graham Number: $3,421,283.77d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Financial Services · Shell Companies New York City, NY, US aimeihealth.com

How the business is doing

Fiscal 2025–2023, USD

Revenue
$0.00
20252023
Net income
$171.4B
20252023
Free cash flow
$0.00
20252023
Total equity
$69.8T
20252023

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2023, USD
FYFYFY
Revenue$0.00$0.00$0.00
Operating income-$-835.76B-$-1.07T-$-28.46B
Net income$1.06T$2.55T$171.4B
EPSd$261.8K$282.7K$19K
Operating cash flow-$-565.1B-$-672.29B$0.00
Capital expenditure$0.00$0.00$0.00
Free cash flow-$-565.1B-$-672.29B$0.00
Total assets$12.1T$73.8T$70.5T
Total debt$2.02T$227.7B$0.00
Net debt$2.02T$199.5B-$-580.72B
Total equity$8.04T$72.3T$69.8T
Cash and short-term investments$2.93B$28.2B$580.7B
Income statement
FYFYFY
Revenue$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00
Research and development expenses$0.00$0.00$0.00
Selling, general and administrative expenses$835.8B$0.00$28.5B
Other expenses$0.00$1.07T$0.00
Operating expenses$835.8B$1.07T$28.5B
Cost and expenses$835.8B$1.07T$28.5B
Interest income$1.9T$3.62T$199.8B
Interest expense$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00
Ebitda-$-835.76B-$-1.07T$171.4B
Operating income-$-835.76B-$-1.07T-$-28.46B
Total other income/expenses, net$1.9T$3.62T$199.8B
Income before tax$1.06T$2.55T$171.4B
Income tax expense$0.00$0.00$0.00
Net income$1.06T$2.55T$171.4B
Weighted average shares outstanding$4.05T$9.03T$9.03T
Weighted average diluted shares outstanding$4.05T$9.03T$9.03T
Balance sheet
FYFYFY
Cash and short-term investments$2.93B$28.2B$580.7B
Net receivables$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Total current assets$2.93B$30.4B$580.7B
Property, plant and equipment, net$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$12.1T$73.8T$69.9T
Total non-current assets$12.1T$73.8T$69.9T
Total assets$12.1T$73.8T$70.5T
Accounts payable$0.00$0.00$0.00
Short-term debt$2.02T$227.7B$0.00
Deferred revenue$0.00$0.00$0.00
Total current liabilities$3.37T$817B$24.8B
Long-term debt$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$690B$690B$690B
Capital lease obligations$0.00$0.00$0.00
Total liabilities$4.06T$1.51T$714.8B
Common stock$12.1T$73.8T$69.9T
Retained earnings-$-4.06T-$-1.48T-$-134.34B
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$8.04T$72.3T$69.8T
Total investments$12.1T$73.8T$69.9T
Total debt$2.02T$227.7B$0.00
Net debt$2.02T$199.5B-$-580.72B
Cash flow statement
FYFYFY
Net income$1.06T$2.55T$171.4B
Depreciation and amortization$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00
Change in working capital$270.7B$392.5B$24.8B
Accounts receivable$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00
Net cash provided by operating activities-$-565.1B-$-672.29B$0.00
Investments in property, plant and equipment$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities$63.6T-$-277.7B-$-69.69T
Common stock issued$0.00$0.00$70.3T
Common stock repurchased-$-65.33T$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities-$-63.04T$397.5B$70.3T
Net change in cash-$-25.28B-$-552.51B$580.7B
Cash at end of period$2.93B$28.2B$580.7B
Operating cash flow-$-565.1B-$-672.29B$0.00
Capital expenditure$0.00$0.00$0.00
Free cash flow-$-565.1B-$-672.29B$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aimei Health Technology Co., Ltd Unit

        Aimei Health Technology Co Ltd operates as a special purpose acquisition company (SPAC), also known as a blank check company.

        CEO
        Junheng Xie
        Employees
        2
        Beta
        0.55

        Explore

        Frequently asked questions

        What is the intrinsic value of Aimei Health Technology Co., Ltd Unit (AFJKU)?

        InvestorsCraft does not currently publish an intrinsic value for AFJKU. How the IC value is calculated.

        Is AFJKU undervalued?

        InvestorsCraft does not publish an undervaluation signal for AFJKU at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.